PSY30 Cost Utility Analysis of the Profilaxis Versus On-Demand Treatment With Recombinant Factor IX for the Treatment of Hemophilia B in Mexico
Jun 1, 2012, 00:00 AM
10.1016/j.jval.2012.03.564
https://www.valueinhealthjournal.com/article/S1098-3015(12)00629-8/fulltext
Section Title :
Systemic Disorders/Conditions
Section Order :
25
First Page :
A103
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(12)00629-8&doi=10.1016/j.jval.2012.03.564